Use of transient elastography (FibroScan®) for the noninvasive assessment of portal hypertension in HIV/HCV-coinfected patients

被引:46
作者
Sanchez-Conde, M. [1 ]
Miralles, P. [1 ]
Maria Bellon, J. [2 ]
Rincon, D. [3 ]
Ramirez, M. [1 ]
Gutierrez, I. [1 ]
Ripoll, C. [3 ]
Lopez, J. C. [1 ]
Cosin, J. [1 ]
Clemente, G. [3 ]
Lo Iacono, O. [3 ]
Banares, R. [3 ,4 ]
Berenguer, J. [1 ]
机构
[1] Hosp Gen Univ Gregorio Maranon, Infect Dis & HIV Unit, Madrid, Spain
[2] Hosp Gen Univ Gregorio Maranon, Biomed Res Fdn, Madrid, Spain
[3] Hosp Gen Univ Gregorio Maranon, Hepatol Unit, Madrid, Spain
[4] Spanish CIBERehd Res Grp, Barcelona, Spain
关键词
hepatitis C infection; HIV infection; liver cirrhosis; liver pathology; HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; VENOUS-PRESSURE GRADIENT; STAGE LIVER-DISEASE; INFECTED PATIENTS; THERAPEUTIC STRATEGIES; NATURAL-HISTORY; FIBROSIS; CIRRHOSIS; PROGRESSION;
D O I
10.1111/j.1365-2893.2010.01371.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The hepatic venous pressure gradient (HVPG) is the gold standard for assessing portal pressure and correlates with the occurrence of portal hypertension (PH)-related complications. Transient elastography (TE) is a new, highly accurate noninvasive technique, which enables us to evaluate hepatic fibrosis to detect advanced fibrosis and cirrhosis. We performed a hepatic haemodynamic study and TE in 38 HIV/HCV-coinfected patients. The association between HVPG and liver stiffness was assessed by linear regression. The diagnostic value of TE was assessed by receiver operating characteristic (ROC) curves. We considered clinically significant PH as an HVPG >= 10 mmHg and severe PH as an HVPG 12 mmHg. A total of 38 HIV/HCV-coinfected patients were included. Twenty-eight patients (73.7%) had clinically significant PH (HVPG >= 10 mmHg), and 23 (60.5%) of these had severe PH (HVPG >= 12 mmHg). We found a statistically significant association between liver stiffness (kPa) and HVPG(r(2) = 0.46, P < 0.001, straight line equation HVPG = 7.4 + 0.204*TE). The areas under the ROC curves were 0.80 [95% confidence interval (CI), 0.64-0.97] and 0.80 (95% CI, 0.66-0.94) for the prediction of HVPG 10 and 12 mmHg, respectively. Our data suggest that TE can predict the presence of clinically significant and severe PH in HIV/HCV-coinfected patients.
引用
收藏
页码:685 / 691
页数:7
相关论文
共 44 条
[1]   Randomized controlled trial of aspiration needle versus automated biopsy device for transjugular liver biopsy [J].
Bañares, R ;
Alonso, S ;
Catalina, MV ;
Casado, M ;
Rincón, D ;
Salcedo, M ;
Alvarez, E ;
Guerrero, C ;
Echenagusía, A ;
Camúñez, F ;
Simó, G .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2001, 12 (05) :583-587
[2]   An algorithm for the grading of activity in chronic hepatitis C [J].
Bedossa, P ;
Poynard, T .
HEPATOLOGY, 1996, 24 (02) :289-293
[3]   Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients [J].
Benhamou, Y ;
Bochet, M ;
Di Martino, V ;
Charlotte, F ;
Azria, F ;
Coutellier, A ;
Vidaud, M ;
Bricaire, F ;
Opolon, P ;
Katlama, C ;
Poynard, T .
HEPATOLOGY, 1999, 30 (04) :1054-1058
[4]   Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data [J].
Berenguer, J. ;
Bellon, J. M. ;
Miralles, P. ;
Alvarez, E. ;
Sanchez-Conde, M. ;
Cosin, J. ;
Lopez, J. C. ;
Alvarez, F. ;
CatalaN, P. ;
Resino, S. .
JOURNAL OF VIRAL HEPATITIS, 2007, 14 (12) :859-869
[5]   Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection [J].
Bica, I ;
McGovern, B ;
Dhar, R ;
Stone, D ;
McGowan, K ;
Scheib, R ;
Snydman, DR .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (03) :492-497
[6]   PORTAL-HYPERTENSION [J].
BOSCH, J ;
NAVASA, M ;
GARCIAPAGAN, JC ;
DELACY, AM ;
RODES, J .
MEDICAL CLINICS OF NORTH AMERICA, 1989, 73 (04) :931-953
[7]   Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease [J].
Bureau, C. ;
Metivier, S. ;
Peron, J. M. ;
Selves, J. ;
Robic, M. A. ;
Gourraud, P. A. ;
Rouquet, O. ;
Dupuis, E. ;
Alric, L. ;
Vinel, J. P. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 27 (12) :1261-1268
[8]   Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? [J].
Burroughs, AK ;
Groszmann, R ;
Bosch, J ;
Grace, N ;
Garcia-Tsao, G ;
Patch, D ;
Garcia-Pagan, JC ;
Dagher, L .
GUT, 2002, 50 (03) :425-427
[9]   Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French departments of internal medicine/infectious diseases, in 1995 and 1997 [J].
Cacoub, P ;
Geffray, L ;
Rosenthal, E ;
Perronne, C ;
Veyssier, P ;
Raguin, G .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (08) :1207-1214
[10]   Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients:: The fibrovic study -: ANRS HC02 [J].
Cacoub, Patrice ;
Carrat, Fabrice ;
Bedossa, Pierre ;
Lambert, Jerome ;
Penaranda, Guillaume ;
Perronne, Christian ;
Pol, Stanislas ;
Halfon, Philippe .
JOURNAL OF HEPATOLOGY, 2008, 48 (05) :765-773